DNA

RhoVac

Spotlight Stockholm: RHOVAC

SEK340m market cap

SEK17.85 last close

RhoVac is an immunotherapy company listed on the Spotlight Stock Market in Sweden, with a 100%-owned subsidiary in Denmark. It is currently developing a peptide-based immunotherapy, RV001, which aims to train the immune system to specifically target cancer cells with metastatic potential.

Investment summary

RhoVac is developing RV001, a cancer immunotherapy designed to prevent or limit metastasis by activating T-cells against cells with metastatic potential. The therapy contains fragments of the protein RhoC, which is overexpressed in cells with metastatic potential across a range of cancers. The recently announced rights issue (SEK154.2m net) is fully committed to by a group of investors, funds from which will be used for a Phase IIb study in prostate cancer (results in H221) and a potential Phase II combination study with a checkpoint inhibitor in a different solid tumour indication. RhoVac will require a partner following positive Phase IIb results.

Y/E Dec
Revenue (SEKm)
EBITDA (SEKm)
PBT (SEKm)
EPS (öre)
P/E (x)
P/CF (x)
2017A 0.0 (12.9) (12.9) (134.0) N/A N/A
2018A 0.0 (20.1) (20.2) (195.0) N/A N/A
2019E 0.0 (37.0) (36.6) (256.0) N/A N/A
2020E 0.0 (50.0) (49.4) (259.0) N/A N/A
Last updated on 25/06/2019
Industry outlook

Metastatic cancer is the most advanced stage of cancer and is terminal. Unfortunately, a large proportion of patients who are diagnosed with cancer already have metastases. Preventing or halting metastasis through inhibiting the metastatic cascade or selectively killing cells with metastatic potential could help to improve survival.

Last updated on 25/06/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (SEKm) 133.6
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (0.8) (47.0) (39.5)
Relative* 0.6 (45.6) (36.5)
52-week high/low SEK52.4/SEK17.9
*% relative to local index
Key management
Anders Ljungqvist CEO